Overview

Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

Status:
Not yet recruiting

Trial end date:
2023-07-31

Target enrollment:

Participant gender:

Summary

The RECOVER study is a self-controlled case series to evaluate whether the addition of Fostemsavir (Rukobia) to a stable HIV regimen in virologically suppressed patients living with HIV who never experience optimal CD4 T-cell count recovery can result in meaningful increases in different immunologic parameters such as CD4 T-cell count, CD4 T-cell percentage and CD4/CD8 ratio

Phase:

Phase 4

Details

Lead Sponsor:

Orlando Immunology Center

Collaborator:

ViiV Healthcare

Treatments:

Fostemsavir